


| Key | % Net Assets |
|---|---|
| 5.0% | |
| 3.5% | |
| 2.9% | |
| 2.8% | |
| 85.8% |
| Name | % Net Assets |
|---|---|
| BG Group | 5.0% |
| Gilead Sciences | 3.5% |
| StatoilHydro ASA | 2.9% |
| AXA S.A. | 2.8% |
| Credit Suisse Group | 2.8% |
| Itau Unibanco Banco Multiplo S.A. ADS | 2.7% |
| GlaxoSmithKline | 2.6% |
| Astrazeneca | 2.6% |
| Lloyds Banking Group | 2.6% |
| Merck & Co. | 2.6% |
No asset data available.
| Date | 20-Aug-2025 |
|---|---|
| NAV | 316.61p |
| Currency | GBP |
| Change | 0.19p |
| % | 0.06% |
| YTD change | 3.85p |
| YTD % | 1.23% |
| Fund Inception | 19/02/2001 |
|---|---|
| Fund Manager | Derek Lygo |
| TER | 0.84 (31-Jan-2013) |
| Minimum Investment | |
|---|---|
| Initial | £500000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 0.75% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.04 |
You are here: research